Telefones: (+351) 217 512 104 ou (+351) 217 573 536
Ligue-se à APES através das redes sociais
facebook
linkedin
twitter
  • HOME
  • APES
    • Objetivos e Enquadramento
    • Orgãos Sociais
    • Mensagem do Presidente
    • Programa da Direção
    • Estatutos
  • ATIVIDADES
    • Agenda
    • Conferências APES
    • Workshops APES
    • Bolsas
    • Prémio Pedro Pita Barros
    • Início de Carreira
  • PUBLICAÇÕES
    • Biblioteca Virtual
    • Repositório de Documentos de Trabalho
    • Documentos de Trabalho APES
  • NEWSLETTER
    • Artigos Newsletter
    • Arquivo
  • ASSOCIADOS
  • CONTACTOS
    • LINKS
  • COVID-19
    • Artigos COVID-19
    • Inquéritos COVID-19
    • Webinars COVID-19

Quarta edição do VECR

07 Outubro, 2020
by Luís Filipe
AES-APES VECR
Comments are off

No dia 13 de Outubro às 13h00 tivemos a quarta edição do Seminário Virtual para investigadores em início de carreira (VERC).

Apresentadora: Carolina Santos (Nova School of Business and Economics, Universidade Nova de Lisboa; Nova Health Economics & Management Knowledge Center), joint work with Eduardo Costa

Título: Pricing, consumption and competition in pharmaceutical drugs: Evidence from changing drugs’ co-payments in Portugal

Resumo: Reference price regimes for prescription drugs are usually implemented with the aim of curbing public expenditure with pharmaceuticals, induce drug substitution from branded to generics drugs
and enhance competition. In these systems, patients co-pay the difference between the drug’s pharmacy retail price and the reimbursement level. Relying on a detailed product-level panel dataset of prescription drugs sold in Portuguese retail pharmacies, from 2016 to 2019, we evaluate the impact of a policy change in the way reference prices are computed, affecting 32% of the equivalent drug groups. We analyse the impact of such change on pricing strategies of pharmaceutical companies and on consumption. Results of a differences-in-differences analysis show that affected products – those subject to a decrease in their reference price – did not reduce their prices, which implied higher prices paid by patients. We found evidence of a 15% decline on branded drugs consumption and no statistically significant effect on generic drug consumption, with signicant heterogeneity across regions and therapeutics. Still, no evidence was found of increased competition in the groups affected by the policy change. Results suggest that NHS co-payments savings were partially achieved through higher out-of-pocket payments paid by patients, raising potential equity concerns.

 

Subscreva a nossa mailing list aqui.

Para alguma questão pode contatar-nos através dos seguintes endereços de email: aesec@aes.es ou earlycareer@apes.pt

Autor
Partilha nas Redes Sociais

Destaques

Vencedor do Prémio Pedro Pita Barros 2020
05 Jan, 2021
Economia da saúde, em tese #2
21 Dez, 2020
No ‘Job Market’: Eduardo Costa
25 Nov, 2020
No 'Job Market': Ana Moura
19 Nov, 2020
Newsletter APES COVID19 #6
11 Nov, 2020
Logótipo APES

Subscrever Newsletter

APES

O que faz a APES
Conferências
Workshops
Apoios e Incentivos
Agenda APES
Inscrições Sócios

Contactos APES

Associação Portuguesa de Economia da Saúde
Escola Nac. de Saúde Pública - UNL
Av. Padre Cruz, 1600-560 Lisboa
Telefone: (+351) 21 751 21 04
ou (+351) 21 757 35 36
Enviar Mensagem
2015 Copyright | Todos os Direitos Reservados | Associação Portuguesa de Economia da Saúde (APES)
www.UnoWork.pt | Serviços Integrados